Replies to post #107003 on Biotech Values

[10nisman]

I think we agreed that the reimbursement comes off the (sales - COGS) number, and is capped at 50% of this number. So if you think the reimbursement was 45 million this quarter, then the (sales - COGS) number would be 90 million. The order of when the reimbursement is taken from the revenue obviously matters.

Thank you for the reply. I thought CW said on one of the cc's that quarterly co-development reimbursement could not exceed 50% of MNTA's share of mLovenox net profit vs 50% of total mLovenox net profit. Where did you and Dew hear it was based on total net profit? Based on your earlier scenario message is it correct to assume you believe MNTA owes ~$60 million in total co-development reimbursement?

Thanks,
10nis

[DFRAI]

Poorgradstudent

How can you develop a model for determing cost of goods for mlovenox? without 100% participation from Novartis and basically "trusting" them to segregate their costs for this particular generic?